In patients with hepatitis C-related cirrhosis, routine screening for hepatocellular carcinoma (HCC) can enable detection of tumors at an earlier, treatable stage and, therefore, is . . .
In patients with hepatitis C-related cirrhosis, routine screening for hepatocellular carcinoma (HCC) can enable detection of tumors at an earlier, treatable stage and, therefore, is associated with increased survival. However, data on the cost-effectiveness and optimal screening interval of this strategy are limited. Researchers constructed a decision analysis with a Markov model to evaluate the cost-effectiveness of no screening versus 4 HCC screening strategies: alpha-fetoprotein (AFP) alone, AFP plus ultrasound (US), AFP plus 3-phase computed tomography (CT), or AFP plus magnetic resonance imaging (MRI). Costs were based on Medicare reimbursement in a hypothetic cohort of patients older than 50 with hepatitis C-related cirrhosis; 80% of …